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Viremia is significantly lower in HIV-2 than in HIV-1 infection, irrespective of disease stage. Never-
theless, the comparable proviral DNA burdens observed for these two infections indicate similar numbers
of infected cells. Here we investigated this apparent paradox by assessing cell-associated viral replication.
We found that untreated HIV-1-positive (HIV-1) and HIV-2 individuals, matched for CD4 T cell
depletion, exhibited similar gag mRNA levels, indicating that significant viral transcription is occurring
in untreated HIV-2 patients, despite the reduced viremia (undetectable to 2.6  104 RNA copies/ml).
However, tat mRNA transcripts were observed at significantly lower levels in HIV-2 patients, suggesting
that the rate of de novo infection is decreased in these patients. Our data also reveal a direct relationship
of gag and tat transcripts with CD4 and CD8 T cell activation, respectively. Antiretroviral therapy
(ART)-treated HIV-2 patients showed persistent viral replication, irrespective of plasma viremia, pos-
sibly contributing to the emergence of drug resistance mutations, persistent hyperimmune activation, and
poor CD4 T cell recovery that we observed with these individuals. In conclusion, we provide here evidence
of significant ongoing viral replication in HIV-2 patients, further emphasizing the dichotomy between
amount of plasma virus and cell-associated viral burden and stressing the need for antiretroviral trials
and the definition of therapeutic guidelines for HIV-2 infection.
HIV-2 infection is characterized by a low or undetectable
plasma viral load (3, 5, 46, 50, 54), in agreement with its
reduced transmission rate (2, 26, 30), providing a natural
model to investigate the relative contribution of HIV replica-
tion to AIDS progression.
Notwithstanding the two-log difference in viremia levels that
characterize HIV-2 and HIV-1 infection, similar levels of cell-
associated viral DNA have been reported, suggesting a com-
parable number of infected cells (6, 24, 45, 52). This apparent
paradox highlights the potential contribution of quiescent la-
tent virus to proviral load and the relevance of quantifying the
ongoing viral replication. The only study, to our knowledge,
addressing transcriptional activity in HIV-2-positive (HIV-2)
patients demonstrated lower gag mRNA expression levels in
HIV-2 than in HIV-1 individuals (34). However, the fact
that these cohorts were not paired for disease stage is a pos-
sible confounding factor, as it is known that gag mRNA levels
are increased in HIV-1 individuals with low CD4 T cell
counts (22, 39).
In spite of the much lower rate of CD4 T cell decline in
HIV-2 than in HIV-1 infection (19, 35), a progressive CD4 T
cell depletion, ultimately leading to AIDS, is observed with
HIV-2 individuals (12, 36). Importantly, despite the lack of
clinical trials of antiretroviral therapy (ART) in HIV-2 infec-
tion, the majority of reports showed poor immunological re-
covery in ART-treated HIV-2 patients, even in the context of
suppression of viremia (1, 19, 29, 40, 51, 56). A rapid emer-
gence of drug-associated mutations in HIV-2 patients under
ART has also been reported (7, 13–15, 25, 29, 41, 47, 48),
suggesting that there is some ongoing viral replication. There
are no data regarding the impact of ART on HIV-2 proviral
DNA levels and/or HIV-2 transcriptional activity.
We have previously shown that CD4 T cell depletion is
directly related to immune activation but only indirectly to
plasma viral load in both HIV-2 and HIV-1 infections (28, 55).
Here we investigate the relationship of CD4 T cell levels and T
cell activation with cell-associated viral burden, measured in
terms of gag and tat mRNA and proviral DNA levels, in par-
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allel with plasma viremia in cohorts of untreated HIV-2 and
HIV-1 individuals together with a cohort of ART-treated
HIV-2 individuals.
MATERIALS AND METHODS
Studied cohorts. We assessed 45 HIV-2 (16 of which were receiving ART)
and 27 untreated HIV-1 patients followed at Hospital de Santa Maria in
Lisbon, Portugal, as well as 16 HIV-seronegative age-matched controls. None of
the patients had ongoing opportunistic infections or tumors. Tables 1 and 2
describe untreated and treated cohorts, respectively. Although HIV-2-infected
cohorts included an increased number of women, non-Caucasian, and elderly
individuals, in the current study these factors were not found to significantly
impact the parameters under analysis (data not shown). All subjects gave in-
formed consent for blood sampling and processing. The study was approved by
the Ethical Board of the Faculty of Medicine, University of Lisbon.
Cell isolation and flow cytometry. Peripheral blood mononuclear cells
(PBMC) were isolated immediately after blood collection and characterized by
flow cytometry as previously described (9).
DNA and mRNA extraction. DNA was extracted from 5  106 PBMC using
the QIAamp DNA minikit. For mRNA extraction, 5  106 PBMC were lysed
(RLT), homogenized (QIAshredder columns), extracted (Oligotex mRNA direct
minikit) (all from Qiagen, Valencia, CA), treated with DNase (DNA-free kit;
Ambion, Austin, TX), and immediately converted to cDNA. Samples were quan-
tified using a NanoDrop ND-1000 spectrophotometer (NanoDrop technologies,
Wilmington, DE).
Viremia and proviral DNA. HIV-1 viremia was quantified by a reverse trans-
criptase PCR (RT-PCR) assay with a detection threshold of 40 RNA copies/ml
(Roche, Basel, Switzerland). HIV-2 viremia was quantified using a previously
described in-house-developed assay with a detection threshold of 200 RNA
copies/ml (54). Quantification of viremia in ART-treated individuals with levels
below 200 RNA copies/ml was repeated using a more sensitive real-time RT-
PCR assay with a detection threshold of 40 RNA copies/ml as described previ-
ously (20). HIV-1 and HIV-2 total viral DNA (integrated and nonintegrated viral
DNA species) was quantified using real-time PCR assays that amplify highly
conserved regions in HIV-1 and HIV-2 gag with a detection range of 7 orders of
magnitude and a sensitivity of 5 copies as we have previously described (52). Test
cutoff values were used to calculate the median and the correlations with other
parameters when levels were below the cutoff.
gag and tat mRNA. Eighty ng of mRNA was reverse transcribed using the
Superscript II reverse transcriptase kit (Invitrogen, Carlsbad, CA), and 250 nM
random hexamers was quantified in duplicate using cDNA (1 g) in a PCR
mixture (50 l) containing 25 l Platinum quantitative PCR SuperMix-UDG, 1
l ROX reference dye (50), 5 mM MgCl2 (all from Invitrogen), and variable
concentrations of the following primers and probes: HIV-1 gag F2 (10 pmol/l),
5-GGGAGAATTAGATCGATGGGAAA-3; HIV-1 gag R1 (10 pmol/l), 5-
GCTCCCTGCTTGCCCATA-3; HIV-1 gag probe, 5-6-carboxyfluorescein
(FAM)-CCCTGGCCTTAACCGAATT-minor groove binder (MGB)-3; HIV-2
gag F2 (10 pmol/l), 5-CGCGAGAAACTCCGTCTTG-3; HIV-2 gag R2 (10
pmol/l), 5-CACACAATATGTTTTAGCCTGTACTTTTT; and probe HIV-2-
gag, 5-FAM-CCGGGCCGTAACCT-MGB-3. tat multiply spliced (MS)
mRNA expression was quantified using the following primers and probes: HIV-1
TABLE 1. Characterization of untreated HIV-2, untreated HIV-1, and seronegative cohortsc
Parameter Seronegative Untreated HIV-2 Untreated HIV-1
No. (male/female) 16 (6/10) 29 (9/20) 27 (18/9)
Median age (range) (yr) 45 (27–57) 52 (19–78)# 39 (23–61)
Ethnicity (Caucasian/other) (no.) 15/1 15/14 20/7
CD4 T cells/l (range) 818 (518–1,312) 568 (52–1,586)* 372 (18–1,848)**
% CD4 T cells (range) 43 (34–61) 28 (7–54)*** 20 (1–47)***
CD8 T cells/l (range) 494 (213–1,109) 788 (271–1,701)** 1065 (177–2,996)***
% CD8 T cells (range) 27 (12–42) 37 (23–74)*** 50 (16–69)***
Viremia (range) (RNA copies/ml)a NA 200 (200–2.6  104)### 1.4  104 (40–4.5  106)
Proviral DNA (range) (copies/106 PBMC)b NA 5 (5–1033) 54 (5–975)
a HIV-2 viremia was below 200 RNA copies/ml (cutoff) in 22 out of 29 patients studied; HIV-1 viremia was below 40 RNA copies/ml (cutoff) in 3 out of 24 patients.
b Proviral DNA was below 5 copies/106 PBMC (cutoff) in 15 out of the 29 HIV-2-infected patients and in 9 out of 24 HIV-1-infected patients investigated.
c NA, not applicable. Values are medians, with limits in brackets. Test cutoff value was used to calculate the median if levels were below cutoff. Significance in
comparison to seronegative: , P  0.05; , P  0.01; , P  0.0001. Significance in comparison to HIV-1: #, P  0.05; ###, P  0.0001.
TABLE 2. Characterization of ART-treated HIV-2 cohortsa
Parameter ART HIV-2 aviremic ART HIV-2 viremic ART HIV-2 (all)
No. (male/female) 11 (5/6) 5 (3/2) 16 (8/8)
Median age (range) (yr) 54 (34–62) 53 (31–62) 54 (31–62)
Current ART regimen (no. of patients)
2 NRTI 3 3
2 NRTI  1 PI 6 4 10
3 NRTI 2 1 3
Length of follow-up (range) (mo)
Under ART 28 (1–109) 66 (6–120) 58 (1–120)
After HIV diagnosis 65 (8–242) 177 (29–220) 97 (8–242)
CD4 T cells/l (range) 340 (70–554) 163 (84–719) 302 (70–719)
% CD4 T cells (range) 22 (5–36) 10 (4–23) 20 (4–36)
CD8 T cells/l (range) 825 (244–1,419) 912 (447–1,532) 887 (244–1,532)
% CD8 T cells (range) 50 (26–64) 53 (49–65) 51 (26–65)
Viremia (RNA copies/ml) (range) 200 4172 (499–34,314) 200 (200–34,314)
Proviral DNA (copies/106 PBMC) (range)b 108 (5–346) 5 (5–726) 57 (5–726.0)
a Values are medians, with limits in brackets. Test cutoff value was used to calculate the median if levels were below cutoff. NRTI, nucleoside RT inhibitor; PI,
protease inhibitor.
b Proviral DNA was below 5 copies/106 PBMC (cutoff) in 5 out of 11 aviremic and in 3 out of 5 viremic treated HIV-2 patients.
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tat F2.3 (6 pmol/l), 5-GACGAAGAGCTCCTCAAGACA-3; HIV-1 tat R2.4
(6 pmol/l), 5-GAGACAGAGACAGATCCGGTC-3; HIV-1 tat probe, 5-
FAM-TCTCTATCAAAGCAACCCGC-MGB-3; HIV-2 tat F3.5 (10 pmol/l),
5-AGGGGCTCGGGATATGTT-3; HIV-2 tat R3.1 (10 pmol/l), 5-TCTGT
ATCCACCGTCGTTTC-3; and HIV-2 tat probe, 5-FAM-TGCATCAGACA
AATC-MGB-3, in an ABI Prism 7000 SDS (Applied Biosystems, Foster City,
CA). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an
internal control (FAM/MGB probe, nonprimer limited; Applied Biosystems;
standard curve with cDNA generated from pooled PBMC from 3 seronegatives).
Standard curves for tat were generated using amplifications of synthetic oligo-
nucleotides (GenScript Corporation, Piscataway, NJ) corresponding to 200-bp
fragments of HIV-1 and HIV-2 tat transcripts, and those for gag were as de-
scribed previously (52). The median values and the correlations with other
parameters were calculated using the tat- and gag-relative quantification values of
patients presenting detectable levels of the transcripts.
HIV-2 sequencing. The in-house methodology was used to sequence a 1,280-bp
HIV-2 pol gene fragment, including the entire protease and part of the reverse
transcriptase from plasma samples. Viral RNA was retrotranscribed and ampli-
fied using the Access RT-PCR core reagents kit (Promega, Madison, WI) and
outer primers JA218 ([1859] 5-GAA AGA AGC CCC GCA ACT TCC-3)
and JA221 ([3258] 5-GCT CTG CTT CTG CTA ATT CTG TCC A-3) as
described previously (54). A nested PCR was performed; a second amplification
was carried out using AmpliTaq Gold PCR master mix and the inner primers
JA219 [(1898) 5-AGG GGC T(A/G)A CAC CAA CAG CAC-3] and
JA220MOD [(3178) 5-GTC TTT ATI CCT GGG TAG AI(T/G) TGT G-3].
Cycle sequencing was accomplished with the BigDye Terminator version 3.1
(v3.1) cycle sequencing kit according to the manufacturer’s recommendations
and using four sequencing primers: JA219, JA220 [(3178) 5-GTC TTT
AT(T/C) CCT GGG TAG ATT TGT G-3], JA222 ([2525]) 5-ACC TCC
AAC TAA TCC TTA TAA TAC C-3), and JA223 ([2625] 5-ACT GAA TTT
CTG TGA AAT CTT GAG T-3). Purified products were run on an ABI Prism
3100 genetic analyzer according to the same protocol but were adjusted to
HIV-2-specific settings; nucleotide sequences were analyzed with SeqScape soft-
ware version 2.5 (all from Applied Biosystems) by alignment with the ROD
HIV-2 reference strain (GenBank accession number M15390).
Statistical analysis. Statistical analysis was performed using GraphPad Prism
version 5.00 (GraphPad Software, Inc., SD) using the Mann-Whitney test, Spear-
man’s coefficient, and Fisher’s exact test. P values of 0.05 were considered
significant. The test cutoff value was used to calculate the median if levels were
below the cutoff.
RESULTS
Ongoing viral replication in untreated HIV-2 infection. In
order to investigate the degree of ongoing viral replication
during the natural history of HIV-2 and HIV-1 infections, we
compared untreated HIV-2 and HIV-1 cohorts matched for
the degree of CD4 T cell depletion (Table 1), although length
of infection was likely greater in HIV-2 than in HIV-1
individuals. As expected, viremia was significantly lower in
HIV-2 than in HIV-1 infection (3, 5, 46, 50, 54). Twenty-two
out of 29 HIV-2 patients had levels below the test cutoff
(aviremic), and the highest viremia was 2.6  104 RNA cop-
ies/ml (Table 1). Conversely, the proviral DNA loads, as pre-
viously reported, were similar (6, 24, 45, 52), suggesting com-
parable numbers of infected cells in these two groups despite
their distinct viremias (Table 1). Of note, although no signifi-
cant correlation was found between proviral DNA and viremia
in HIV-2 infection, significantly higher proviral levels were
found in viremic than in “aviremic” individuals (P  0.0396).
tat mRNA, a multiply spliced (MS) HIV transcript, is thought
to be expressed mainly in recently infected cells and/or cells ac-
tively producing virus (31, 32, 38, 53). We found a significantly
higher number of individuals with undetectable tat mRNA in the
HIV-2 than in the HIV-1 cohort (P 0.0014; Fisher’s exact test).
Moreover, HIV-2 patients with detectable tat mRNA featured
significantly lower levels than their HIV-1 counterparts (Fig.
1A), and a significant correlation with viremia was observed only
with the HIV-1 cohort (r  0.4791, P  0.0443, n  19 for the
HIV-1 cohort; r  0.0312, P  0.9349, n  8 for the HIV-2
cohort). Although no correlation with CD4 T cell levels were
observed (Table 3), individuals with low CD4 T cell counts tended
to have higher levels of tatmRNA (see Fig. 1 posted at http://www
.imm.fm.ul.pt/dl/SoaresEtAlSupplementalFigure1AndLegend
.pdf).
Conversely, gag mRNA, an unspliced (US) HIV transcript,
was similarly expressed in the HIV-1 and HIV-2 cohorts (Fig.
1B), which included an equal number of individuals with un-
detectable expression levels. Of note, no correlation with vire-
mia was found for either infection.
Furthermore, on comparing viremic and aviremic HIV-2
individuals, we observed no significant differences between the
number of patients with detectable tat and gag mRNA tran-
scripts, and we found similar levels of expression of tat and gag
mRNA (Fig. 1A and B), although these results should be
interpreted cautiously, given the small number of individuals
assessed.
A low ratio of gag to tat mRNA levels has been suggested as
a marker of active viral transcription and of HIV-1 disease
progression (22, 37, 49). We found a significantly higher gag-
to-tat ratio in HIV-2 than in HIV-1 patients (P  0.0118),
although no association with viremia was found in either co-
hort.
Of note, neither tat nor gag mRNA expression levels nor the
gag-to-tat ratio significantly correlated with the proviral DNA
load in either HIV cohort. Moreover, when we subdivided the
HIV-1 and HIV-2 cohorts on the basis of detectable and un-
detectable viral mRNA, no differences in proviral DNA levels
were observed (Fig. 1C and D). Thus, no direct relationship
appears to exist between the number of infected cells, as esti-
mated by proviral DNA, and the levels of tat and gag transcrip-
tion in PBMC during untreated HIV-2 and HIV-1 infections,
suggesting a significant contribution of archived viral DNA.
Overall, HIV-2 individuals exhibited reduced levels of tat
and similar levels of gag transcripts compared to their HIV-1
counterparts, translating into a higher gag-to-tat mRNA ratio
in the former.
Relationship of plasma and cell-associated viral load with
CD4 T cell depletion and T cell activation in HIV-2 infection.
We have previously shown that T cell activation markers were
similarly upregulated in HIV-1 and HIV-2 infections when
patients were matched for CD4 T cell levels, suggesting that
CD4 T cell depletion is more directly linked to immune acti-
vation than to viral load (28, 55). Here, we assessed the rela-
tionship between cell-associated viral mRNA and DNA and
the hyperimmune activation observed for HIV-2 and HIV-1
infections.
With respect to gag mRNA expression, we found a direct
correlation with the levels of HLA-DR expression (Table 3)
and HLA-DR and CD38 coexpression (r 0.5150; P 0.0287)
within CD4 T cells in HIV-2 individuals; this correlation did
not reach statistical significance in HIV-1 individuals. No
correlations were found with CD8 T cell activation levels (Ta-
ble 3).
Conversely, we observed that the levels of tat mRNA in
HIV-1 individuals directly correlated with CD8 T cell activa-
tion levels, measured either as the proportion of HLA-DR
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CD38 (Table 3) or CD38 cells (r  0.6196; P  0.0047), as
well as CD38 mean fluorescence intensity (MFI; r  0.7386;
P  0.0003). Clear trends for an association between tat
mRNA levels and CD8 T cell activation were also observed
with the HIV-2 cohort, but no significant correlations were
found with CD4 T cell activation in either infection (Table 3).
Of note, proviral DNA levels did not directly correlate with
either CD4 or CD8 T cell activation in HIV-1 and HIV-2
individuals (Table 3), further suggesting that a significant com-
ponent comprises archived quiescent virus.
In spite of the narrow range of HIV-2 viremia (undetectable
to 26,263 copies/ml), significant positive correlations were
found between viremia and several T cell activation markers
(Table 3) (percentage of HLA-DR CD38 within CD4 T
cells: r  0.5685, P  0.0013; percentage and MFI of CD38
within CD8 T cells: r 0.6196, P 0.0047, and r 0.5330, P
FIG. 1. tat and gag mRNA expression and proviral DNA levels in untreated HIV-2 and HIV-1 infections. Graphs show the expression of tat
(A) and gag (B) (as arbitrary units) relative to GAPDH in those individuals with detectable levels of these transcripts, from a total of 25 HIV-2
and 23 HIV-1 individuals evaluated. Open symbols refer to patients with viremia below the cutoff of the test, and closed symbols to patients with
detectable viremia. Proviral DNA levels were compared for untreated HIV-2 (25 of 25) and HIV-1 (20 of 23) individuals with detectable and
undetectable tat (C) and gag (D) mRNA transcripts. Bars represent medians.
TABLE 3. Correlations between virological parameters and levels of CD4 T cells and immune activation in
untreated HIV-2 and HIV-1 infections
Viremia, DNA,
or transcript Virus type
r; Pa
% CD4 T cells CD4 T cells/l % HLA-DR
 in
CD4 T cells
% HLA-DR 38 in
CD8 T cells
Viremia HIV-2 0.3097; 0.1021 0.3943; 0.0343 0.5186; 0.0039 0.5288; 0.0032
HIV-1 0.6120; 0.0009 0.5810; 0.0019 0.4731; 0.0146 0.7140; <0.0001
Proviral DNA HIV-2 0.0313; 0.8719 0.1555; 0.4207 0.2281; 0.2339 0.1029; 0.5952
HIV-1 0.0652; 0.7621 0.1019; 0.6358 0.0005; 0.9983 0.1590; 0.4580
tat mRNA HIV-2 0.5952; 0.1323 0.5238; 0.1966 0.6190; 0.1017 0.6667; 0.0831
HIV-1 0.3737; 0.1150 0.3193; 0.1827 0.2825; 0.2413 0.5404; 0.0169
gag mRNA HIV-2 0.5728; 0.0130 0.3870; 0.1126 0.4985; 0.0353 0.3189; 0.1971
HIV-1 0.2281; 0.3477 0.1869; 0.4435 0.4018; 0.0882 0.4193; 0.0739
a Test cutoff values were used to calculate the correlations with viremia or proviral DNA, if levels were below the cutoff. Correlations with viral mRNA were
calculated using the tat and gag relative quantification values of patients presenting detectable levels of the transcripts (8 and 18 in HIV-2, respectively, and 19 for both
tat and gag in HIV-1). Statistically significant correlations are represented in bold.
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0.0029, respectively). In order to further assess the relative
contribution of viremia, we compared viremic and aviremic
HIV-2 individuals (Table 1). Although the former showed
significantly higher CD4 and CD8 T cell activation than the
latter (Fig. 2A and B), both viremic and aviremic HIV-2
individuals had significantly higher levels of T cell activation
than seronegatives did (Fig. 2A and B) and exhibited strong
negative correlations between CD4 T cell numbers and CD4
and CD8 T cell activation levels (Fig. 2C and D).
Overall, our data not only demonstrated that T cell activa-
tion was strongly associated with CD4 T cell depletion, both in
viremic and aviremic HIV-2 individuals, but also supported a
contribution, even at low levels, of circulating virus to both
CD4 and CD8 T cell activation. Moreover, we showed that gag
mRNA was directly related to CD4 T cell activation and tat
mRNA to CD8 T cell activation, suggesting an overall impact
of viral transcripts upon T cell activation.
Cell-associated viral mRNA and DNA in HIV-2 patients
under ART. In order to further dissect the impact of cell-
associated viral DNA and RNA upon HIV-2 immunopatho-
genesis, we assessed these parameters in patients receiving
ART (Table 2). This cohort exhibited significantly lower CD4
T cell counts than untreated HIV-2 individuals did (P 
0.0046), in agreement with previous reports showing a limited
CD4 T cell recovery in ART-treated HIV-2 infection (1, 19, 29,
40, 51, 56). Viremia levels were similar in the treated and
untreated HIV-2 cohorts, due to the low-level viremia detected
in some of the ART-treated HIV-2 patients (Table 2).
Of note, in contrast with the progressive decline in proviral
DNA levels usually observed with ART-treated HIV-1 pa-
tients (23, 58), proviral DNA did not significantly differ be-
tween untreated and treated HIV-2 patients (Fig. 3A), de-
spite the prolonged treatment. Moreover, treated and
untreated HIV-2 patients featured similar levels of gag mRNA
expression, whereas tat expression was significantly higher in
the treated cohort, although the reduced number of individuals
with detectable tat transcripts preclude a definitive interpreta-
tion (Fig. 3A). No significant differences were found between
the number of patients with detectable tat and gag mRNA
transcripts within treated and untreated groups. These results
FIG. 2. Relationship between viremia, absolute CD4 T cell numbers, and T cell activation in untreated HIV-2 infection. Proportion of CD4 T
cells expressing HLA-DR (A) and CD8 T cells coexpressing HLA-DR and CD38 (B) in seronegative individuals (white bars) and untreated HIV-2
patients (dark gray bars). HIV-2 patients were further stratified into viremic (black bars) and aviremic groups (light gray bars). Bars represent
median interquartile range. Correlations between CD4 T cell depletion and proportion of cells expressing HLA-DR within the CD4 T cell subset
(C) and proportion of CD8 T cells coexpressing HLA-DR and CD38 (D).
VOL. 85, 2011 HIV-2 VERSUS HIV-1 CELL-ASSOCIATED BURDEN 2433
FIG. 3. Impact of ART on HIV-2 plasma and cell-associated viral load, CD4 T cell frequency, and T cell activation. (A) Levels of proviral DNA
and tat and gag mRNA (expressed as arbitrary units) were compared in untreated and ART-treated HIV-2 individuals. Open symbols represent
patients with viremia below the cutoff of the test, and closed symbols patients with detectable viremia. Bars represent medians. (B) Longitudinal
study of a representative ART-treated HIV-2 patient. Day 0 was defined as the therapy initiation date. The vertical dashed lines indicate the
periods under specific ART regimens (ABC, abacavir; 3TC, lamivudine; AZT, zidovudine; LPV, lopinavir; RTV, ritonavir; FTC, emtricitabine;
TDF, tenofovir). Mutations in protease (PR) and reverse transcriptase (RT) were analyzed before therapy (day 37) and after the first ART
regimen (day 108). Mutations [amino acid changes] found before therapy (day37) were, in PR, Y14H, N40S, N41D, N68G, K69[K, R], and K70R
and, in RT, D17[E, D], W24[G, W], K28R, C38[W, C], K43[K, R], K64R, L74V, K82R, D123G, P126Q, H162Y, V167I, K176S, H228D, W235[G,
C, W], and Q245E. Mutations found after first therapy (day 108) were, in PR, Y14H, N40S, N41D, N68G, K69R, and K70R and, in RT, K28R,
K43[K, R], K64R, W71R, L74I, K82R, T88[T, P], H96[H, P], G99[A, G], D123G, P126[Q, P], I159[I, L], H162Y, V167I, K176S, M184V, I187[I,
L], and L209[P, L]. Proportion of CD4 T cells expressing HLA-DR (C) and CD8 T cells coexpressing HLA-DR and CD38 (D) in seronegative
individuals (white bars) and ART-treated HIV-2 individuals (dark gray bars). HIV-2 patients were further stratified into viremic (black bars)
and aviremic groups (light gray bars). Bars represent median  interquartile range.
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showed significant amounts of ongoing viral replication in
ART-treated HIV-2 infection, suggesting a limited effective-
ness of the ART regimens in HIV-2 infection, which justifies
further exploration in large cohorts treated with optimized
ART regimens.
Additionally, neither the amount of gag and tat transcripts
nor proviral DNA significantly differed between treated HIV-2
patients with detectable and undetectable viremia (Fig. 3A),
emphasizing that the absence of detectable viremia is not a
good surrogate marker for cell-associated viral mRNA and/or
DNA during HIV-2 infection.
A rapid emergence of mutations potentially associated with
drug resistance has been reported for HIV-2 patients under
ART (25, 29, 41). We confirmed the presence of mutations in
the reverse transcriptase and protease in our ART-treated
HIV-2 cohort (Table 4). These data further support the pres-
ence of significant amounts of ongoing replication in these
ART-treated HIV-2 patients, leading us to speculate about
the potential contribution of ART-induced selective pressure
upon the virus to the increased tat transcript levels (Fig. 3).
The selection of adequate ART regimens to treat HIV-2
infection is difficult given the lack of clinical trials. There are
currently some phenotypic studies that allow the selection of
better first-line therapies than those used a few years ago (16,
61), but the knowledge of HIV-2 resistance pathways is still
incomplete. Longitudinal data of an individual HIV-2 pa-
tient, in whom the initial ART regimen was associated with the
rapid emergence of mutations and virological failure, illus-
trated that switching to another ART combination was associ-
ated with viremia suppression and a decline of cell-associated
viral burden (Fig. 3B). This was supported by both a loss of
measurable tat and gag transcripts and a decrease in the levels
of proviral DNA, both of which are indicative of a successful
virological response. Nevertheless, this patient’s immunologi-
cal response was limited, with only marginal CD4 T cell recov-
ery and a partial decrease in both CD4 and CD8 T cell immune
activation (Fig. 3B), suggesting that factors other than viral
replication are contributing to the poor immunological recon-
stitution. Our findings support a role for persistent immune
activation, given that, as shown in Fig. 3C and D, ART-treated
HIV-2 individuals exhibited significantly higher levels of T
cell activation than seronegatives did, similar levels of CD4 and
CD8 T cell activation in comparison with the untreated HIV-2
cohort, and significant negative correlations between absolute
CD4 T cell numbers and the percentages of HLA-DR within
CD4 T cells (r0.5147; P 0.0413) and HLA-DR CD38
within CD8 T cells (r  0.5294; P  0.0350).
Overall, significant amounts of ongoing viral replication
were observed with HIV-2-infected patients under ART, high-
lighting the importance of additional studies of antiretroviral
TABLE 4. Virological parameters and CD4 T cell levels of HIV-2 patients under ARTd
Case
no. Current ART regimen
Follow-up after
HIV diagnosis/
under ART
(mo)a
CD4 T pre-ART;
post-ART
(cells/l)a
Mutations Viremia (RNAcopies/ml)
Proviral DNA
(copies/106
PBMC)
tat mRNA
(arbitrary units)
gag mRNA
(arbitrary units)
1 d4T  3TC  SQV/rb 177/108 300; 719 NA 4,172 5 Undet 1.07  102
2 AZT/3TC/ABC 63/63 138; 554 NA 40 5 Undet 9.82  101
3 AZT/3TC 26/26 457; 535 PR  RTc 40 5 2.13  101 Undet
4 AZT/3TCb 206/64 500; 520 NA 44 158 Undet Undet
5 AZT/3TC  LPV/r 126/26 125; 457 NA 40 114 Undet 3.56  102
6 AZT/3TC  LPV/r 38/28 164; 406 NA 40 108 Undet 4.46  101
7 AZT/3TC/ABC 242/61 287; 340 PR  RTc 191 5 ND ND
8 AZT/3TC  SQV/r 8/5 222; 326 NA 40 145 Undet Undet
9 AZT/3TC  NFVb 29/4 143; 277 PR  RTc 499 5 3.14  101 1.72  101
10 AZT/3TC 15/1 297; 273 NA 40 126 Undet Undet
11 AZT/3TC  IDV/r 65/51 112; 251 NA 40 346 5.19  102 1.91
12 AZT/3TC/ABC 220/56 176; 163 PR  RTc 742 187 Undet 7.25  101
13 AZT/3TC  IDVb 218/6 121; 102 PR  RTc 40 5 3.73  101 3.30  103
14 d4T  3TC  SQV/rb 177/120 82; 87 NA 34,314 726 ND ND
15 AZT/3TC  LPV/rb 67/12 120; 84 PR  RTc 10,474 5 Undet Undet
16 ABC/FTC  LPV/rb 216/7 128; 70 NA 40 5 Undet Undet
a ART refers to the current therapy.
b Previous ART regimens included the following: case 1, AZT, ddI, ddC; case 4, ddC, d4T; case 9, ddI, EFV; case 13, d4T; case 14, AZT, ddI; case 15, ddI, d4T,
NFV; case 16, AZT.
c The following mutations (amino acid change) were found (those mutations previously associated with drug resistance are in bold). Case 3: for PR, P19S, N61D,
E65K, L99F; for RT, V5L, K9R, I10V, M11T, E44	K, R, E, G
, K68G, R72	K, R
, K82R, D86E, Q91	Q, P
, P126Q, H162Y, V167I, K173R, K176Q, I179T, E197G,
R200K, Y227F, H228Q. Case 7: for PR, Y14	H, Y
, N40S, N61D, E65	K, R
, K70R; for RT, M11T, E44	E, D
, K82R, P126Q, H162Y, V167I, K176Q, M184V, D218	E,
D
, E219D, D224	N, D
, P226	P, S
, H228Q, W239	G, W
, Q245H, L246W, Q248L, E250D, I251T, K259N, N265I, W266G. Case 9: for PR, E21D, N40S, T56	T, A
,
V62	A, V
, K70R, V71I, L99F; for RT, V5I, M11T, D17	E, D
, P51S, D76V, F77L, R78G, E79K, P126Q, S134A, V167I, K176P, I180L, M184V, H228Q, E250G, I251V,
K259N, N265I. Case 12: for PR, Y14H, N40S, N41	N, D
, I46	I, V
, N61	N, D
, E65R, D79E; for RT, K9R, I10V, M11T, R22K, K35R, K40R, P51S, K70Q, D86E,
R104	K, R
, V111I, P126Q, S134A, V167I, K176P, I180	I, L
, M184V, S215Y, F221L, D224N, H228Q. Case 13: PR, Y14H, N40S, E65R, K70R, F85L, I89V, L90 M;
for RT, A3V, V5M, I10V, M11R, K43R, T53S, T58S, T60	T, P
, T88	T, P
, P126Q, A138T, V167I, A174T, K176P, I180L, M184V, H228Q, K243	K, R
. Case 15: for
PR, K7R, V10I, V22I, V33I, E37D, N40S, I54 M, T56V, N68G, K70R, V71I, M76L, I82F, I89	I, V
, T91A, G94	S, G
; for RT, P1	P, L
, V5	I, V
, I10	I, V
, D17	N,
D
, E48	E, G
, A62	A, V
, K64	K, R
, K65	K, R
, A101P, P126Q, P126Q, V135A, Q151M, H162Y, V167I, K176P, I180L, M184V, I189L, V201A, F214L, D218	K, N,
E, D
, E219	E, D
, H228K, V254F.
d ND, not done; Undet, undetectable mRNA expression; NA, no amplification; ART, antiretroviral therapy; reverse transcriptase (RT) inhibitors: AZT, zidovudine;
3TC, lamivudine; ABC, abacavir; d4T, stavudine; ddC, zalcitabine; ddI, didanosine; EFV, efavirenz; FTC, emtricitabine; r, ritonavir. Protease (PR) inhibitors: LPV,
lopinavir; IDV, indinavir; NFV, nelfinavir; SQV, saquinavir.
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drug efficacy in HIV-2 infection. Furthermore, ART appar-
ently failed to have a significant impact on T cell activation,
even in patients with undetectable viremia, possibly contribut-
ing to their low CD4 T cell recovery.
DISCUSSION
Here we demonstrated that untreated HIV-1 and HIV-2
individuals with similar degrees of CD4 T cell depletion fea-
tured similar levels of gag mRNA transcripts, suggesting that
significant viral transcription occurs in HIV-2 patients, despite
the lower viremia. Conversely, we found decreased levels of tat
mRNA in untreated HIV-2 individuals. Given the previous
reports demonstrating that HIV-1 tat mRNA transcripts accu-
mulate and outnumber gag mRNA transcripts in recently in-
fected cells (31, 32, 38, 53), our results provide evidence for a
decreased rate of de novo cell infection in HIV-2 disease.
Proviral DNA levels have been used to estimate the extent
of viral reservoirs (8, 10, 11, 18). We and others have shown
that the levels of total proviral DNA are similar in the two HIV
infections despite the reduced viremia observed with HIV-2
individuals (6, 45, 52). This may result from a preferential
contribution of latently infected, quiescent T cells to total
HIV-2 proviral DNA. Alternatively, a significant amount of
ongoing viral replication occurs, but it does not translate into
plasma viral load. In this study, we showed that the levels of
proviral DNA were not associated with viral transcription lev-
els in HIV-1 or in HIV-2 individuals, bringing into question
the reliability of proviral DNA levels as a marker of replicative
activity in both infections.
Additionally, the impact of plasma and cell-associated viral
load upon HIV-2-associated hyperimmune activation was in-
vestigated. Of note, significantly higher levels of CD4 and CD8
T cell activation were found in viremic individuals than in
aviremic individuals, despite the small amount of circulating
virus observed with viremic HIV-2 patients. In agreement
with a recent report on an African cohort (33), our data sup-
port a contribution of plasma viral load, even at low levels, to
immune activation, which may be related to transmission of
cell free viruses and/or immunological effects of viral proteins.
The direct association between gag mRNA and CD4 T cell
activation that we observed with HIV-infected patients raises
the possibility that ongoing viral replication significantly con-
tributes to the maintenance of heightened T cell activation in
HIV-2 individuals in spite of the reduced viremia. In addi-
tion, the direct association found between tat mRNA levels
and CD8 T cell activation, particularly in HIV-1 individuals,
suggests a specific role of this transactivator molecule and/or
newly infected cells in driving CD8 T cell activation.
With respect to HIV-1 infection, those rare (0.1%) indi-
viduals who are able to control viral replication in the absence
of ART (27, 42, 44, 60) provide another valuable resource for
the investigation of factors associated with viremia control.
Various criteria have been used to define this population,
including viremia ranging from undetectable (elite controllers)
up to 2,000 RNA copies/ml (viremic controllers) (42, 60). No-
tably, the small cohort of HIV-1 controllers within our un-
treated HIV-1 cohort resembles the untreated HIV-2 cohort in
terms of viremia, gag and tat mRNA expression, gag-to-tat
ratio, and proviral DNA levels. The seven individuals with
viremia of 2,000 RNA copies/ml tended to have lower levels
of tat mRNA (14.59  14.47 arbitrary units) than the other
HIV-1 patients did (262.0  210.4 arbitrary units), though
the levels did not reach statistical significance. The numbers of
patients with detectable tat mRNA, gag mRNA, and proviral
DNA were similar within these subgroups of the HIV-1 cohort,
and no differences in gag mRNA levels or proviral DNA were
observed, but the gag-to-tat ratio was higher in controllers (P
0.0434). These data further support that viremia control is
associated with reduced levels of tat transcripts.
Finally, we provide evidence of persistent HIV-2 replication
during ART, based on proviral DNA and gag and tat mRNA
levels, irrespective of detectable plasma viremia. We also dem-
onstrated drug-related genetic evolution of HIV-2 reverse
transcriptase and protease gene sequences. The high levels of
tat mRNA observed with the ART-treated HIV-2 cohort sug-
gested that the therapeutic regimens used were unable to re-
duce the rate of de novo cell infection. These data contrast with
those for ART-treated HIV-1 patients, in which virological
response is usually associated with a sharp decline in MS
mRNA (4, 21, 62) and in the proportion of MS mRNA relative
to US mRNA in PBMC (57), as well as with a progressive
decrease in proviral DNA (23, 58, 59) despite the low-level
viremia that can frequently be detected using ultrasensitive
assays (17, 43).
In agreement with previous reports (1, 19, 29, 40, 51), we
documented poor CD4 T cell recovery in ART-treated HIV-2
individuals, even in those with evidence of viral suppression. Our
findings suggest that persistent hyperimmune activation may be a
main determinant of this impaired immune reconstitution. The
study of lymphoid tissue from HIV-2-infected patients will be
instrumental in evaluating the degree of irreversible damage as-
sociated with long-term infection that may limit the potential for
immune recovery and providing support for an early start of ART
in this otherwise relatively benign disease.
In conclusion, we provide here evidence of ongoing viral
replication in HIV-2 infection despite the low or undetectable
viremia and of its association with CD4 and CD8 T cell activation,
with the latter being more closely related to the levels of tat
mRNA. Of particular note was the persistent viral replication in
ART-treated HIV-2 individuals. In light of these findings, par-
ticularly the apparent ease with which the virus mutated in treated
HIV-2 individuals to escape drug activity, there is an obvious
need for large-scale drug trials for HIV-2 infection to determine
the most appropriate drug regimen and also the benefit of an
early initiation of therapy for this infection.
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